newsFDA approves innovative engineered cell therapy2 August 2024 | By Catherine Eckford (European Pharmaceutical Review)The accelerated approval by the US Food and Drug Administration (FDA) authorises the first engineered cell therapy for a solid tumour in the US.
newsNew cell therapy company will treat solid tumours8 March 2023 | By Catherine Eckford (European Pharmaceutical Review)Adaptimmune Therapeutics and TCR² Therapeutics’ new cell therapy company could gain the first approval for an engineered T-cell receptor (TCR) T-cell therapy for a solid tumour.
articleBuilding an integrated vector supply to support autologous cell therapy for solid tumours9 November 2022 | By James Nanista, Josh HuntFacing limited viral vector manufacturing capacity, should companies consider further integrating their viral vector supply to address this issue? James Nanista and Josh Hunt of Adaptimmune reflect on the options.
newsBreakthrough Therapy designation for Adaptimmune’s NY-ESO-1-T cell therapy10 February 2016 | By Victoria WhiteThe Breakthrough Therapy designation was based on the results of a Phase I/II trial in patients with unresectable, metastatic or recurrent synovial sarcoma...
newsAdaptimmune initiates Phase I/II T-cell therapy study in NSCLC18 December 2015 | By Victoria WhiteThis will be the first study of Adaptimmune’s unpartnered affinity enhanced T-cell therapy targeting MAGE-A10, a highly immunogenic member of the MAGE-A family of cancer testis antigens...
